KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $55.7 million.

  • Halozyme Therapeutics' Other Non-Current Assets fell 30.51% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 30.51%. This contributed to the annual value of $80.6 million for FY2024, which is 352.38% up from last year.
  • Halozyme Therapeutics' Other Non-Current Assets amounted to $55.7 million in Q3 2025, which was down 1.19% from $56.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Other Non-Current Assets registered a high of $80.6 million during Q4 2024, and its lowest value of $13.4 million during Q4 2021.
  • Its 3-year average for Other Non-Current Assets is $43.4 million, with a median of $52.5 million in 2024.
  • In the last 5 years, Halozyme Therapeutics' Other Non-Current Assets tumbled by 32.26% in 2023 and then soared by 352.38% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Other Non-Current Assets stood at $13.4 million in 2021, then skyrocketed by 96.07% to $26.3 million in 2022, then plummeted by 32.26% to $17.8 million in 2023, then skyrocketed by 352.38% to $80.6 million in 2024, then crashed by 30.51% to $55.7 million in 2025.
  • Its last three reported values are $55.7 million in Q3 2025, $56.4 million for Q2 2025, and $55.6 million during Q1 2025.